Affitech changes its top management
Affitech A/S has recruited two senior biopharmaceutical company executives from outside the company to lead its management team following the company’s merger in May 2009 with Pharmexa A/S.
News
FDA asks SkyePharma to do more clinical work on Flutiform
The Food and Drug Administration has asked SkyePharma Plc to provide more clinical data for its asthma treatment, Flutiform, thereby extending its review of the Flutiform new drug application (NDA) into 2011, the UK company said.
Innate Pharma says it has cash to support its operations into 2011
Innate Pharma SA said that it has sufficient cash to finance its clinical programmes into 2011 even as it steps up development of its candidate products for cancer. A Phase 2a trial of a monoclonal antibody for multiple myeloma is set to start soon.
Norway supports Clavis with grant for pancreatic cancer trial
The Norwegian government has awarded Clavis Pharma ASA up to $1.1 million to accelerate its early clinical-stage treatment for pancreatic cancer, intravenous CP-4126. The grant was made by Innovation Norway, a state-owned company.
Roflumilast said to show improved lung function in Phase 3 COPD studies
Roflumilast, a phosphodiesterase 4 (PDE4) inhibitor, has been reported to show an improvement in lung function in patients with chronic obstructive pulmonary disease in four Phase 3 trials published in The Lancet. The drug is produced by Nycomed.
Ablynx nearly doubles revenues in 2009 first half
Ablynx NV nearly doubled its revenues to €11.9 million in the first half of 2009 following milestone payments from its research collaborators, Novartis, Wyeth, Boehringer Ingelheim and Merck Serono.
Santaris to receive $6.5 million for access to its locked nucleic acid drug platform
Santaris Pharma A/S is to receive $6.5 million upfront from Shire Plc for giving the UK company access to its locked nucleic acid (LNA) drug platform for identifying drug candidates against certain targets to treat rare genetic disorders.
ProStrakan to receive $10 million upfront for testosterone product
The UK specialty pharmaceutical company, ProStrakan Group Plc, is to receive $10 million upfront in an exclusive licensing and distribution deal with Endo Pharmaceuticals Inc for its testosterone replacement therapy, Fortesta.
Newly merged Affitech plans to raise capital
Affitech A/S, a therapeutic antibody company that was created in May 2009 by the merger of a privately-owned Norwegian company and Pharmexa A/S of Denmark, plans to raise new equity capital this year to finance its antibody programme.
Ark expects EMEA opinion on gene therapy by the end of 2009
Ark Therapeutics Group Plc said that it expects a regulatory decision on its application to market a novel gene therapy in Europe for patients with malignant glioma, a type of brain cancer, by the end of 2009.